Stimulation of platelet death by vancomycin

Cellular Physiology and Biochemistry

Volumn 31, Issue 1, 2013, Pages 102-112

  Towhid, Syeda T ^a   Schmidt, Eva Maria ^a   Tolios, Alexander ^a,b   Münzer, Patrick ^a   Schmid, Evi ^a   Borst, Oliver ^a,b   Gawaz, Meinrad ^b   Stegmann, Evi ^a   Lang, Florian ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Apoptosis; Caspase 3; Cell membrane scrambling; Mitochondrial potential; Phosphatidylserine; Platelets

Indexed keywords

ALPHA2BBETA3 INTEGRIN; CASPASE 3; CERAMIDE; INTEGRIN; PADGEM PROTEIN; PHOSPHATIDYLSERINE; THROMBOXANE B2; UNCLASSIFIED DRUG; VANCOMYCIN; ALPHA3 INTEGRIN; FLUO 3; LACTATE DEHYDROGENASE; LIPOCORTIN 5;

ADULT; APOPTOSIS; ARTICLE; BIOSYNTHESIS; CALCIUM CELL LEVEL; CELL MEMBRANE SCRAMBLING; CELL VOLUME; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MEMBRANE DAMAGE; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE POTENTIAL; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE STRUCTURE; THROMBOCYTOPENIA; CELL DEATH; CELL STIMULATION; CELL SURFACE; DEPOLARIZATION; FLUORESCENCE; IMMUNOFLUORESCENCE; MECHANICAL STRESS; THROMBOCYTE; THROMBOCYTE MEMBRANE; THROMBOCYTE RICH PLASMA; THROMBOCYTE VOLUME; UPREGULATION;

EID: 84873039699     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000343353     Document Type: Article

References (45)

1. Vandecasteele SJ, De Vriese AS: Recent changes in vancomycin use in renal failure. Kidney Int 2010;77:760-764.
2. Anand A, Chauhan HK: Piperacillin and vancomycin induced severe thrombocytopenia in a hopsitalized patient. Platelets 2011;22:294-301.
3. Kenney B, Tormey CA: Acute vancomycin-dependent immune thrombocytopenia as an anamnestic response. Platelets 2008;19:379-383.
4. Nasraway SA, Shorr AF, Kuter DJ, O'Grady N, Le VH, Cammarata SK: Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin Infect Dis 2003;37:1609-1616.
5. Christie DJ, van Buren N, Lennon SS, Putnam JL: Vancomycin-dependent antibodies associated with thrombocytopenia and refractoriness to platelet transfusion in patients with leukemia. Blood 1990;75:518-523.
6. Mizon P, Kiefel V, Mannessier L, Mueller-Eckhardt C, Goudemand J: Thrombocytopenia induced by vancomycin-dependent platelet antibody. Vox Sang 1997;73:49-51.
7. Okamoto H: Vancomycin-induced immune thrombocytopenia. N Engl J Med 2007;356:2537-2538.
8. Von Drygalski A, Curtis BR, Bougie DW, McFarland JG, Ahl S, Limbu I, Baker KR, Aster RH: Vancomycin-induced immune thrombocytopenia. N Engl J Med 2007;356:904-910.
9. Kile BT: The role of the intrinsic apoptosis pathway in platelet life and death. J Thromb Haemost 2009;7 Suppl 1:214-217.
10. Akinnusi ME, Hattemer A, Gao W, El Solh AA: Does linezolid modulate lung innate immunity in a murine model of methicillin-resistant Staphylococcus aureus pneumonia? Crit Care Med 2011;39:1944-1952.
11. Leytin V, Allen DJ, Mykhaylov S, Lyubimov E, Freedman J: Thrombin-triggered platelet apoptosis. J Thromb Haemost 2006;4:2656-2663.
12. Towhid ST, Schmidt EM, Schmid E, Munzer P, Qadri SM, Borst O, Lang F: Thymoquinone-induced platelet apoptosis. J Cell Biochem 2011;112:3112-3121.
13. Zhang W, Liu J, Sun R, Zhao L, Du J, Ruan C, Dai K: Calpain activator dibucaine induces platelet apoptosis. Int J Mol Sci 2011;12:2125-2137.
14. Varga-Szabo D, Braun A, Nieswandt B: STIM and Orai in platelet function. Cell Calcium 2011;50:270-278.
15. del Conde I, Cruz MA, Zhang H, Lopez JA, Afshar-Kharghan V: Platelet activation leads to activation and propagation of the complement system. J Exp Med 2005;201:871-879.
16. Smyth SS, McEver RP, Weyrich AS, Morrell CN, Hoffman MR, Arepally GM, French PA, Dauerman HL, Becker RC: Platelet functions beyond hemostasis. J Thromb Haemost 2009;7:1759-1766.
17. Prevost N, Woulfe D, Tognolini M, Brass LF: Contact-dependent signaling during the late events of platelet activation. J Thromb Haemost 2003;1:1613-1627.
18. Wonerow P, Pearce AC, Vaux DJ, Watson SP: A critical role for phospholipase Cgamma2 in alphaIIbbeta3-mediated platelet spreading. J Biol Chem 2003;278:37520-37529.
19. Kulkarni S, Woollard KJ, Thomas S, Oxley D, Jackson SP: Conversion of platelets from a proaggregatory to a proinflammatory adhesive phenotype: role of PAF in spatially regulating neutrophil adhesion and spreading. Blood 2007;110:1879-1886.
20. American Thoracic Society, Infectious Diseases Society of America: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:377-416.
21. Bastani B, Minton J, Islam S: Insufficient penetration of systemic vancomycin into the PermCath lumen. Nephrol Dial Transplant 2000;15:1035-1037.
22. Giuliano C, Haase KK, Hall R: Use of vancomycin pharmacokinetic- pharmacodynamic properties in the treatment of MRSA infections. Expert Rev Anti Infect Ther 2010;8:95-106.
23. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A: High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006;166:2138-2144.
24. Lodise TP, Miller CD, Graves J, Evans A, Graffunder E, Helmecke M, Stellrecht K: Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2008;62:1138-1141.
25. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, Stellrecht K: Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008;52:3315-3320.
26. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM: Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004;42:2398-2402.
27. Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, Alamo D, Ortega M, Lopez J, Mensa J: Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46:193-200.
28. Tenover FC, Moellering RC Jr: The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007;44:1208-1215.
29. Young LS: Hematologic effects of linezolid versus vancomycin. Clin Infect Dis 2004;38:1065-1066.
30. Baugh RF, Jacoby C, Brown JE, Hougie C: Effect of vancomycin on ristocetin and bovine PAF-induced agglutination of human platelets. Thromb Res 1978;12:511-521.
31. Coller BS, Lundberg WB, Gralnick HR: Effects of vancomycin on platelets, plasma proteins and hepatitis B surface antigen. Thromb Diath Haemorrh 1975;34:83-93.
32. Coller BS, Gralnick HR: Studies on the mechanism of ristocetin-induced platelet agglutination. Effects of structural modification of ristocetin and vancomycin. J Clin Invest 1977;60:302-312.
33. Coller BS: Polybrene-induced platelet agglutination and reduction in electrophoretic mobility: enhancement by von Willebrand factor and inhibition by vancomycin. Blood 1980;55:276-281.
34. Moake JL, Cimo PL, Peterson DM, Roper P, Natelson EA: Inhibition of ristocetin-induced platelet agglutination by vancomycin. Blood 1977;50:397-406.
35. Lang F, Gulbins E, Lang PA, Zappulla D, Foller M: Ceramide in suicidal death of erythrocytes. Cell Physiol Biochem 2010;26:21-28.
36. Lang KS, Myssina S, Brand V, Sandu C, Lang PA, Berchtold S, Huber SM, Lang F, Wieder T: Involvement of ceramide in hyperosmotic shock-induced death of erythrocytes. Cell Death Differ 2004;11:231-243.
37. Wolf BB, Goldstein JC, Stennicke HR, Beere H, Amarante-Mendes GP, Salvesen GS, Green DR: Calpain functions in a caspase-independent manner to promote apoptosis-like events during platelet activation. Blood 1999;94:1683-1692.
38. Randriamboavonjy V, Fleming I: All cut up! The consequences of calpain activation on platelet function. Vascul Pharmacol 2012;56:210-215.
39. Towhid ST, Nega M, Schmidt EM, Schmid E, Albrecht T, Münzer P, Borst O, Gawaz M, Götz F, Lang F: Stimulation of platelet apoptosis by peptidoglycan from Staphylococcus aureus 113. Apoptosis 2012;17:998-1008.
40. Hoffmann M, Lopez JJ, Pergola C, Feisst C, Pawelczik S, Jakobsson PJ, Sorg BL, Glaubitz C, Steinhilber D, Werz O: Hyperforin induces Ca2+-independent arachidonic acid release in human platelets by facilitating cytosolic phospholipase A2 activation through select phospholipid interactions. Biochim Biophys Acta 2010;1801:462-472.
41. Poeckel D, Tausch L, Kather N, Jauch J, Werz O: Boswellic acids stimulate arachidonic acid release and 12-lipoxygenase activity in human platelets independent of Ca2+ and differentially interact with platelet-type 12-lipoxygenase. Mol Pharmacol 2006;70:1071-1078.
42. Bogatcheva NV, Sergeeva MG, Dudek SM, Verin AD: Arachidonic acid cascade in endothelial pathobiology. Microvasc Res 2005;69:107-127.
43. Borst O, Schmidt EM, Munzer P, Schonberger T, Towhid ST, Elvers M, Leibrock C, Schmid E, Eylenstein A, Kuhl D, May AE, Gawaz M, Lang F: The serum-and glucocorticoid-inducible kinase 1 (SGK1) influences platelet calcium signaling and function by regulation of Orai1 expression in megakaryocytes. Blood 2012;119:251-261.
44. Schoenwaelder SM, Yuan Y, Josefsson EC, White MJ, Yao Y, Mason KD, O'Reilly LA, Henley KJ, Ono A, Hsiao S, Willcox A, Roberts AW, Huang DC, Salem HH, Kile BT, Jackson SP: Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood 2009;114:663-666.
45. Ruggero MA, Abdelghany O, Topal JE: Vancomycin-induced thrombocytopenia without isolation of a drug-dependent antibody. Pharmacotherapy 2012;32:e321-e325.